SCHEMBL18558207

SCHEMBL18558207

Cc1ccc(-c2cc(N/C(=N\C(=O)c3ccc(F)c(F)c3)NC3CCCC3)[nH]n2)cc1F

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MLLT3 P42568 1/20 0.37
MLLT1 Q03111 1/20 0.37
NPC1 O15118 2/20 0.36
RAB9A P51151 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
WNT1 P04628 1/20 0.36
DYRK1A Q13627 1/20 0.36
TAS1R3 Q7RTX0 1/20 0.35
TAS1R1 Q7RTX1 1/20 0.35
TAS1R2 Q8TE23 1/20 0.35
TSHR P16473 1/20 0.35
HTT P42858 1/20 0.35
EPHX2 P34913 1/20 0.35
TP53 P04637 3/20 0.35
LMNA P02545 2/20 0.35
MAPT P10636 2/20 0.35
CYP3A4 P08684 2/20 0.35
CYP2D6 P10635 1/20 0.35
CYP2C9 P11712 1/20 0.35
KCNH2 Q12809 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18558211 0.98 WNT1 (0.36) MLLT3MLLT1NPC1RAB9ASMN1; SMN2
SCHEMBL18558490 0.89 RAB9A (0.40) MLLT3MLLT1NPC1RAB9ASMN1; SMN2
SCHEMBL18558530 0.89 TRPV1 (0.38) MLLT3MLLT1
SCHEMBL18558315 0.87 KDM5B (0.38) MLLT3MLLT1NPC1RAB9ASMN1; SMN2
SCHEMBL18558297 0.87 NR1H4 (0.38) MLLT3MLLT1NPC1RAB9ASMN1; SMN2
SCHEMBL18558093 0.87 MAPK14 (0.38) MLLT3MLLT1HDAC6
SCHEMBL18558166 0.86 NPC1 (0.41) NPC1RAB9ASMN1; SMN2WNT1DYRK1A
SCHEMBL18558514 0.85 HDAC1 (0.36) NPC1RAB9ANR1H4HDAC1HDAC6
SCHEMBL18558169 0.85 MAPK14 (0.41) ABL1HDAC6PDE4APDE4BPDE4C
SCHEMBL18558660 0.84 HDAC1 (0.36) HDAC1HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9932313-B2 Pyrazolyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof LYCERA CORPORATION (US) 2018-04-03 US disclosed
US-20170267643-A1 PYRAZOLYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF WILMINGTON TRUST, NATIONAL ASSOCIATION 2017-09-21 US disclosed
US-9580388-B2 Pyrazolyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof LYCERA CORPORATION (US) 2017-02-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170267643-A1 PYRAZOLYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF ATP5F1A, ATP5F1D, ATP5ME MLLT3 3676/4885MLLT1 4180/4885NPC1 1877/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.